Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis

被引:61
作者
Eitzman, DT
Bodary, PF
Shen, YC
Khairallah, CG
Wild, SR
Abe, A
Shaffer-Hartman, J
Shayman, JA
机构
[1] Univ Michigan, Med Ctr, Div Cardiol, Ann Arbor, MI 49109 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷 / 02期
关键词
D O I
10.1097/01.ASN.0000043901.45141.D4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Fabry disease is an X-linked lysosomal storage disorder due to deficiency of a-galactosidase A (GLA) activity that results in the widespread accumulation of neutral glycosphingolipids. Renal failure, neuropathy, premature myocardial infarction, and stroke occur in patients with this condition primarily due to deposition of glycosphingolipids in vascular endothelial cells. The clinical consequences of Fabry disease suggest that vascular thrombosis may play a prominent role in the pathogenesis of this disease; however, the vasculopathy associated with Fabry disease has not been extensively studied. To determine if mice genetically deficient in Gla are susceptible to vascular thrombosis, a photochemical carotid injury model was used to induce occlusive thrombosis. In this model, Gla-/0 mice displayed a progressive age-dependent shortening of the time to occlusive thrombosis after vascular injury that correlated with progressive accumulation of globotriasylceramide (Gb3) in the arterial wall. Bone marrow transplantation from Gla-/0 to Gla+/0 mice and from Gla+/0 to Gla-/0 mice did not change the thrombotic phenotype of the host. These studies reveal a potent vascular prothrombotic phenotype in Gla-deficient mice and suggest that antithrombotic therapies as well as therapies designed to reduce the vascular accumulation of Gb3 may have beneficial effects on thrombotic complications in patients with Fabry disease.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 22 条
  • [1] Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation
    Abe, A
    Gregory, S
    Lee, L
    Killen, PD
    Brady, RO
    Kulkarni, A
    Shayman, JA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) : 1563 - 1571
  • [2] Enhanced endothelium-dependent vasodilation in Fabry disease
    Altarescu, G
    Moore, DF
    Pursley, R
    Campia, U
    Goldstein, S
    Bryant, M
    Panza, JA
    Schiffmann, R
    [J]. STROKE, 2001, 32 (07) : 1559 - 1562
  • [3] Effect of leptin on arterial thrombosis following vascular injury in mice
    Bodary, PF
    Westrick, RJ
    Wickenheiser, KJ
    Shen, YC
    Eitzman, DT
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1706 - 1709
  • [4] ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY
    BRADY, RO
    GAL, AE
    BRADLEY, RM
    MARTENSS.E
    WARSHAW, AL
    LASTER, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) : 1163 - &
  • [5] DeGraba T, 2000, ANN NEUROL, V47, P229, DOI 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO
  • [6] 2-T
  • [7] Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733, DOI DOI 10.1036/ommbid.181
  • [8] Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
    Eitzman, DT
    Westrick, RJ
    Nabel, EG
    Ginsburg, D
    [J]. BLOOD, 2000, 95 (02) : 577 - 580
  • [9] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16
  • [10] FABRY DISEASE - AN UNUSUAL CAUSE OF SEVERE CORONARY-DISEASE IN A YOUNG MAN
    FISHER, EA
    DESNICK, RJ
    GORDON, RE
    ENG, CM
    GRIEPP, R
    GOLDMAN, ME
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (03) : 221 - 223